The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma

References

• Attal M, Harousseau JL. Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–7
   PubMed Web of Science ®Google Scholar
• Kim H, Sohn HJ, Kim S, et al. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006; 37: 1037–42
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579–85
   PubMed Web of Science ®Google Scholar
• Porrata LF, Litzow MR, Tefferi A, et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002; 16: 1311–8
   PubMed Web of Science ®Google Scholar
• Schrama JG, Rodenhuis S, de Gast GC. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 2003; 31: 141–2
   PubMedGoogle Scholar
• Gordan LN, Sugrue MW, Lynch JW, et al. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 31: 1009–13
   PubMed Web of Science ®Google Scholar
• Porrata LF, Inwards DJ. Micallef IN et al. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol 2002; 117: 629–33
   PubMed Web of Science ®Google Scholar
• Yoong Y, Porrata LF, Inwards DJ, et al. The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma. Leuk Lymphoma 2005; 46: 1287–94
   PubMed Web of Science ®Google Scholar
• Siddiqui MA, Markovic SN, Nevala WK, et al. Day 15 natural killer (NK) cell recovery predicts progression free survival after autologous stem cell transplantation in non-Hodgkin's lymphoma. ASH Annual Meeting Abstracts. Blood 2006; 108: 2914
   PubMed Web of Science ®Google Scholar
• Joao C, Porrata LF, Inwards DJ, et al. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplant 2006; 37: 865–71
   PubMed Web of Science ®Google Scholar
• Boulassel MR, Herr AL, de B Edwards MD, et al. Early lymphocyte recovery following autologous peripheral stem cell transplantation is associated with better survival in younger patients with lymphoproliferative disorders. Hematology 2006; 11: 165–70
   PubMed Web of Science ®Google Scholar
• Kim H, Sohn HJ, Kim SE, et al. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 34: 43–9
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gertz MA, Litzow MR, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res 2005; 11: 1210–8
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gertz MA, Geyer SM, et al. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2004; 18: 1085–92
   PubMed Web of Science ®Google Scholar
• Porrata LF, Litzow MR, Inwards DJ, et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 291–8
   PubMed Web of Science ®Google Scholar
• Hiwase DK, Hiwase S, Bailey M, et al. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2008; 14: 116–24
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–23
   PubMed Web of Science ®Google Scholar
• Oliveira MR, Hyashi M, Magalhaes-Silverman M. Early lymphocyte recovery predicts for progression-free survival (PFS) in Hodgkin's lymphoma (HL) patients following autologous stem cell transplant (ASCT) using same ablative regimen. Blood 2002; 100 (suppl): 2551
   Web of Science ®Google Scholar
• Ferrandina G, Pierelli L, Perillo A, et al. Lymphocyte recovery in advanced ovarian cancer patients after high-dose chemotherapy and peripheral blood stem cell plus growth factor support: clinical implications. Clin Cancer Res 2003; 9: 195–200
   PubMed Web of Science ®Google Scholar
• Holtan SG, Porrata LF, Inwards DJ, et al. Time interval from last chemotherapy to stem cell collection correlates with peripheral blood absolute lymphocyte count at apheresis and survival post-autologous stem cell transplantation in non-Hodgkin's lymphoma. ASH Annual Meeting Abstracts. Blood 2004; 104: 2927
   Web of Science ®Google Scholar
• Holtan SG, Porrata LF, Inwards DJ, et al. Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma. Br J Haematol 2006; 133: 628–33
   PubMed Web of Science ®Google Scholar
• Hiwase DK, Bollard G, Hiwase S, et al. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy 2007; 9: 539–47
   PubMed Web of Science ®Google Scholar
• Porrata LF, Hayman SR, Gertz MA, et al. The role of stem cell mobilization regimen on lymphocyte collection yield and survival after autologous hematopoietic stem cell transplantation in multiple myeloma. ASH Annual Meeting Abstracts. Blood 2005; 106: 1174
   Google Scholar
• Porrata LF, Gastineau DA, Pineda A, et al. Increasing the number of apheresis collections increases lymphocyte collection and affects survival after autologous stem cell transplantation for non-Hodgkin lymphoma. ASH Annual Meeting Abstracts. Blood 2004; 104: 892
   Web of Science ®Google Scholar
• Theilgaard-Monch K, Raaschou-Jensen K, Palm H, et al. Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogeneic stem cell grafts. Bone Marrow Transplant 2001; 28: 1073–82
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gastineau DA, Padley D, et al. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma 2003; 44: 997–1000
   PubMed Web of Science ®Google Scholar
• Condomines M, Quittet P, Lu ZY, et al. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. J Immunol 2006; 176: 6631–9
   PubMed Web of Science ®Google Scholar
• Tayebi H, Kuttler F, Saas P, et al. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. Exp Hematol 2001; 29: 458–70
   PubMed Web of Science ®Google Scholar